Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

NCT02864992 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT02864992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02864992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 13, 2016
Completion date
August 31, 2026
Enrollment
337 (actual)
Sites
176

Conditions

As the registry lists them; a condition with its own page is linked.

advanced (stage iiib/iv) non-small cell lung cancer (nsclc) with met exon 14 (metex14) skipping alterations or met amplification, lung adenocarcinoma stage iiib/iv